Boryung has achieved its highest-ever first-half performance, driven by the expansion of its global business.
The company reported consolidated revenue of 535 billion won and an operating profit of 44 billion won for the first half of the year, as announced on August 6. Compared to the same period last year, revenue increased by 42.9 billion won (8.7%), and operating profit rose by 7.7 billion won (21.1%). Gross profit also grew to 199.2 billion won, up by 15.1 billion won (8.2%). The operating profit margin improved to 8.2%, reflecting an increase from the previous year.
This performance was bolstered by stable growth from existing products and the addition of revenue from global operations.
Sales from the cytotoxic anticancer drug Taxotere (generic name docetaxel), acquired from France's Sanofi last year, began to contribute to global revenue starting in June. Boryung has secured global rights, including distribution, licensing, production, and trademark rights for Taxotere, covering markets worldwide, including South Korea.
Additionally, the company commenced contract development and manufacturing (CDMO) services for cytotoxic anticancer drugs from its Yeongju campus in the first half of the year, further diversifying its revenue structure. Boryung is leveraging this foundation to expand its business from a domestic prescription-focused model to the global pharmaceutical market.
New product successes also contributed to the results. The hypertension and dyslipidemia treatment Canavjet (pimasartan, atorvastatin, and ezetimibe), launched in May, achieved initial sales of 3.7 billion won in the first half.
Since launching Canav, South Korea's first hypertension new drug, Boryung has continued to release products in the Canav family. Notably, despite the impact of a price reduction for the hypertension drug Canav (generic name pimasartan), which was reflected in provisions, the Canav family recorded second-quarter sales of 38.8 billion won. Excluding provisions, this represents a 23% increase compared to the same period last year.
A Boryung official stated, "Since the acquisition of Taxotere, we have begun to see global sales, and the combination of CDMO supply and new product launches is driving our growth. The results confirm the success of our business structure transformation and demonstrate the structural stability of our portfolio."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.